Free Trial

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals logo
$614.79 +18.25 (+3.06%)
As of 05/20/2025 04:00 PM Eastern

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
22

Based on 26 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 3 have given a hold rating, 19 have given a buy rating, and 3 have given a strong buy rating for REGN.

Consensus Price Target

$890.60
44.86% Upside
According to the 26 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $890.60. The highest price target for REGN is $1,200.00, while the lowest price target for REGN is $150.00. The average price target represents a forecasted upside of 44.86% from the current price of $614.79.
Get the Latest News and Ratings for REGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors.

Sign Up

REGN Analyst Ratings Over Time

TypeCurrent Forecast
5/21/24 to 5/21/25
1 Month Ago
4/21/24 to 4/21/25
3 Months Ago
2/21/24 to 2/20/25
1 Year Ago
5/22/23 to 5/21/24
Strong Buy
3 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
19 Buy rating(s)
17 Buy rating(s)
16 Buy rating(s)
15 Buy rating(s)
Hold
3 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$890.60$963.56$973.13$989.36
Forecasted Upside44.86% Upside71.61% Upside39.81% Upside-0.46% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Regeneron Pharmaceuticals Stock vs. The Competition

TypeRegeneron PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.81
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside44.86% Upside4,843.17% Upside13.03% Upside
News Sentiment Rating
Positive News

See Recent REGN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/14/2025Citigroup
3 of 5 stars
G. Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$600.00 ➝ $700.00+21.92%
5/1/2025Guggenheim
2 of 5 stars
Yatin Suneja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$940.00 ➝ $810.00+37.47%
4/30/2025Truist Financial
2 of 5 stars
Srikripa Devarakonda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$975.00 ➝ $940.00+58.66%
4/30/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Salveen Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$917.00 ➝ $804.00+36.25%
4/30/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$750.00 ➝ $700.00+19.35%
4/30/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Abrahams
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$1,051.00 ➝ $943.00+60.78%
4/30/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Evan David Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$865.00 ➝ $800.00+37.68%
4/30/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$768.00 ➝ $633.00+9.41%
4/25/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Skorney
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$759.00 ➝ $652.00+8.71%
4/22/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$695.00+23.78%
4/17/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tim Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderperform ➝ Underperform$575.00 ➝ $547.00-0.42%
3/31/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chris Schott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$1,100.00 ➝ $1,000.00+57.72%
2/5/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
2/5/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$762.00 ➝ $834.00+19.65%
2/4/2025TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$1,230.00 ➝ $1,030.00+48.22%
2/4/2025Bernstein Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$1,070.00 ➝ $1,000.00+44.18%
1/27/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$1,195.00 ➝ $1,013.00+47.20%
1/7/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$1,110.00 ➝ $1,070.00+47.03%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$1,150.00+46.96%
11/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$1,150.00 ➝ $1,000.00+20.56%
11/1/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,235.00 ➝ $1,184.00+41.27%
11/1/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,080.00 ➝ $1,065.00+25.91%
10/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$1,250.00 ➝ $1,175.00+24.93%
6/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,060.00 ➝ $1,170.00+9.97%
11/28/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$935.00 ➝ $937.00+17.00%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$800.00-2.77%
11/3/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$950.00+16.02%
9/15/2023Westpark Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
6/28/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/28/2023500.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
6/28/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:15 AM ET.


Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 19, 2025. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • The current stock price is around $594, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for price appreciation.
  • The company reported a net margin of over 31%, showcasing its ability to generate profit relative to its revenue, which is a positive indicator of financial health.
  • Recent institutional investments, including a significant purchase by Raiffeisen Bank International AG, suggest confidence in the company's future performance.
  • Analysts predict earnings per share of approximately 35.92 for the current fiscal year, indicating potential for strong profitability moving forward.

Regeneron Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • The company recently missed earnings expectations, reporting $8.22 per share compared to the consensus estimate of $8.83, which may raise concerns about its growth trajectory.
  • Revenue for the last quarter was down about 3.7% compared to the same period last year, indicating potential challenges in maintaining sales growth.
  • Some analysts have downgraded their price targets for the stock, reflecting a cautious outlook on its near-term performance.
  • The company has a relatively low dividend yield of 0.59%, which may not attract income-focused investors looking for higher returns.
  • With a debt-to-equity ratio of 0.09, while low, it may indicate limited leverage for growth opportunities compared to competitors with higher ratios.

REGN Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $890.60, with a high forecast of $1,200.00 and a low forecast of $150.00.

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 19 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.

According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 44.86% based on their 12-month stock forecasts.

Over the previous 90 days, Regeneron Pharmaceuticals's stock had 2 upgrades by analysts.

Analysts like Regeneron Pharmaceuticals more than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.92 while the average consensus rating score for "medical" companies is 2.81. Learn more on how REGN compares to other companies.


This page (NASDAQ:REGN) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners